Pluristem CEO Zami Aberman Re-Elected to Alliance for Regenerative Medicine’s Board of Directors
October 13 2016 - 7:00AM
Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading
developer of placenta-based cell therapy products, today announced
its Chairman and CEO, Zami Aberman, has been re-elected as Member
of the Board of Directors of the Alliance for Regenerative Medicine
(ARM). This is Mr. Aberman’s second year serving on the Board of
the Washington, D.C.-based, international organization that
represents the gene therapy, cell therapy and tissue engineering
sector. Pluristem has been a member of ARM for 4 years and has
actively supported the organization’s goals.
Mr. Aberman will work with fellow board members,
officers and executive committee members of ARM who come from the
leading companies and institutions in regenerative medicine, to set
the overall vision and direction of ARM.
“I am honored to be re-elected to the Board of
ARM. Over the past year, Pluristem has made a meaningful
contribution to this very important organization, which advances
the regenerative medicine industry for the benefit of patients and
healthcare systems around the globe,” stated Pluristem CEO Zami
Aberman.
About The Alliance for Regenerative
MedicineThe Alliance for Regenerative Medicine (ARM) is an
international multi-stakeholder advocacy organization that promotes
legislative, regulatory and reimbursement initiatives necessary to
facilitate access to life-giving advances in regenerative medicine
worldwide. ARM also works to increase public understanding of the
field and its potential to transform human healthcare, providing
business development and investor outreach services to support the
growth of its member companies and research organizations. Prior to
the formation of ARM in 2009, there was no advocacy organization
operating in Washington, D.C. to specifically represent the
interests of the companies, research institutions, investors and
patient groups that comprise the entire regenerative medicine
community. Today, ARM has more than 225 members and is the leading
global advocacy organization in this field. To learn more about ARM
or to become a member, visit http://www.alliancerm.org.
About Pluristem
Therapeutics
Pluristem Therapeutics Inc. is a leading
developer of placenta-based cell therapy products. The Company has
reported robust clinical trial data in multiple indications for its
patented PLX (PLacental eXpanded) cells. The cell products release
a range of therapeutic proteins in response to inflammation,
ischemia, hematological disorders, and radiation damage. PLX cell
products are grown using the Company's proprietary
three-dimensional expansion technology. They are off-the-shelf,
requiring no tissue matching prior to administration.
Pluristem has a strong intellectual property
position; Company-owned and operated, GMP-certified manufacturing
and research facilities; strategic relationships with major
research institutions; and a seasoned management team.
Contact:
Pluristem Therapeutics Inc.
Karine Kleinhaus, MD, MPH
Divisional VP, North America
1-914-512-4109
karinek@pluristem.com
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Sep 2023 to Sep 2024